amylin


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to amylin: Symlin

am·y·lin

 (ăm′ə-lĭn)
n.
1. A peptide hormone that is secreted along with insulin by the beta cells of the pancreas and helps to regulate blood sugar levels by inhibiting glucagon secretion and by slowing the rate at which food leaves the stomach.
2. Archaic Any of various components of starch.
Mentioned in ?
References in periodicals archive ?
M2 EQUITYBITES-August 24, 2017-Boehringer Ingelheim launches phase one clinical trials to evaluate glucagon/GLP-1 agonist and an amylin analogue
M2 PHARMA-August 24, 2017-Boehringer Ingelheim launches phase one clinical trials to evaluate glucagon/GLP-1 agonist and an amylin analogue
Scientists from Boston University School of Medicine (BUSM) also found that pramlintide improves learning and memory and AD patients have a lower level of amylin in blood compared to those without this disease.
A study conducted at UC-Davis is the first to recognize deposits of a protein called amylin in the brains of people with Alzheimer's disease (AD), along with combined deposits of amylin and plaques.
Gergen is a healthcare industry veteran and most recently was Senior Vice President, Corporate Development for Amylin Pharmaceuticals, Inc.
and AstraZeneca PLC have expanded their diabetes alliance through Bristol-Myers' recent acquisition of Amylin Pharmaceuticals Inc.
9 August 2012 - US pharmaceutical group Bristol-Myers Squibb Co (NYSE:BMY) said on Thursday it had finalised its acquisition of Amylin Pharmaceuticals Inc (NASDAQ:AMLN) for USD5.
Even as Human Genome Sciences rejected GSK's extended tender as "not reflecting an accurate valuation," New York-based Bristol-Myers Squibb (NYSE: BMY) agreed to acquire San Diego diabetes drug-maker Amylin Pharmaceuticals (NASDAQ: AMLN) for $7 billion - the fourth billion-dollar plus deal and the largest in the pharmaceutical industry this year.
RELATED ARTICLE: Lilly, Amylin End Diabetes Alliance
Along-acting formulation of exenatide as failed to pass muster with the Food and Drug Administration, which is asking the manufacturer Amylin for its most recent clinical trial results and a new QT prolongation analysis.
Amylin is a normal secretory product of pancreatic beta cells, and it plays an important role in controlling nutrient fluctuations.
Amylin Pharmaceuticals (a company based in San Diego, California) has developed BYETTA (exenatide) injections, which is an approved treatment for type 2 diabetes that is injected subcutaneously twice a day.